A randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ethyl-ester omega-3 fatty acid in Taiwanese hypertriglyceridemic patients
Journal
Journal of Atherosclerosis and Thrombosis
Journal Volume
24
Journal Issue
3
Pages
275-289
Date Issued
2017
Author(s)
Wang K.-Y.
Charng M.-J.
Tsai W.-C.
Vige R.
Olivar J.E.R.
Tseng C.-D.
Abstract
AIM: , a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients. METHODS: ) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment. RESULTS: 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study. CONCLUSIONS: may be a feasible option to treat hypertriglyceridemia in Taiwanese patients.
SDGs
Publisher
Japan Atherosclerosis Society
Type
journal article